Table 1.
Baseline demographics and clinical characteristics of patient enrolled in this study
| Characteristic | Conventional DMARD group (n = 406) | Biologic DMARD group (n = 396) | p value |
|---|---|---|---|
| Age, yr | 57.0 ± 12.2 | 54.2 ± 12.3 | 0.0010 |
| Female sex | 325 (80.1) | 345 (87.1) | 0.0069 |
| Disease duration, yr | 5.9 ± 6.6 | 7.8 ± 7.5 | < 0.0001 |
| Rheumatoid factor, IU/mL | 281.9 ± 687.0 | 215.2 ± 324.1 | 0.9845 |
| Anti-CCP, IU/mL | 267.6 ± 598.0 | 262.2 ± 524.6 | 0.1300 |
| ESR, mm/hr | 51.7 ± 26.3 | 58.6 ± 26.0 | 0.0002 |
| CRP, mg/dL | 2.84 ± 5.51 | 2.59 ± 3.48 | 0.4318 |
| SDAI | 25.69 ± 10.90 | 32.08 ± 12.98 | < 0.0001 |
| DAS28-ESR | 4.70 ± 0.71 | 5.23 ± 0.80 | < 0.0001 |
| TJC, n (0–28) | 6.9 ± 4.4 | 10.2 ± 6.1 | < 0.0001 |
| SJC, n (0–28) | 5.3 ± 3.5 | 7.4 ± 5.0 | < 0.0001 |
| PGA, cm (0–10) | 5.3 ± 2.1 | 6.0 ± 2.2 | < 0.0001 |
| MDGA, cm (0–10) | 5.4 ± 2.1 | 5.9 ± 2.1 | 0.0020 |
| HAQ | 1.00 ± 0.73 | 1.33 ± 0.75 | < 0.0001 |
| Previous DMARD use, % | |||
| Conventional | 88.9 | 100 | - |
| Biologic | 6.7 | 20.7 | - |
| Corticosteroid use, % | 92.1 | 85.9 | - |
Values are presented as mean ± SD or number (%).
DMARD, disease-modifying antirheumatic drug; CCP, cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; SDAI, simplified disease activity index; DAS, disease activity score; TJC, tender joint count; SJC, swollen joint count; PGA, patient global assessment; MDGA, physician global assessment; HAQ, Health Assessment Questionnaire.